Arvinas Inc (ARVN)
32.82
+0.39
(+1.20%)
USD |
NASDAQ |
May 03, 16:00
32.90
+0.08
(+0.26%)
After-Hours: 20:00
Arvinas Research and Development Expense (Annual): 379.70M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 379.70M |
| December 31, 2022 | 315.00M |
| December 31, 2021 | 180.40M |
| December 31, 2020 | 108.40M |
| Date | Value |
|---|---|
| December 31, 2019 | 67.20M |
| December 31, 2018 | 45.19M |
| December 31, 2017 | 28.79M |
| December 31, 2016 | 19.94M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
67.20M
Minimum
2019
379.70M
Maximum
2023
210.14M
Average
180.40M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Pfizer Inc | 10.68B |
| Bristol-Myers Squibb Co | 9.299B |
| Janux Therapeutics Inc | 54.92M |
| Geron Corp | 125.05M |
| Verastem Inc | 61.36M |